Abstract 107P
Background
Metastatic non-clear cell renal cell carcinoma (mnccRCC) currently lacks standard first-line treatment options. This study evaluated the effectiveness and safety of ICI plus tyrosine kinase inhibitor (TKI) in mnccRCC patients through multi-center real-world evidence, encompassing the largest sample size to date.
Methods
We conducted a retrospective analysis of treatment-naive metastatic non-clear cell renal cell carcinoma (mnccRCC) patients who received either TKI monotherapy or TKI + ICI combination therapy at four hospitals in China. Baseline characteristics were recorded, and comparisons were made between the two groups in terms of objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and the incidence of adverse events (AEs).
Results
A total of 214 mnccRCC patients were enrolled from the four hospitals: 122 in the TKI monotherapy group and 92 in the TKI + ICI combination group. The median follow-up time was 36.5 months (interquartile range [IQR], 24.2–57.0), with a median age of 49 years and a majority of male patients (70.6%). Compared to the TKI group, the TKI + ICI group showed a significantly higher objective response rate (29.4% vs. 16.4%, P < 0.01) and disease control rate (78.3% vs. 48.4%, P < 0.01). Additionally, the combination therapy group had a longer progression-free survival [median PFS (95% CI): 15.2 (6.6–23.7) months vs. 5.9 (4.3–7.5) months, P < 0.001] and a longer overall survival [median OS (95% CI): not reached vs. 38.5 (26.6–50.4) months, P = 0.019]. The incidence of grade 3 or higher treatment-related adverse events was slightly higher in the combination therapy group, but the difference was not statistically significant (35.8% vs. 23.7%, P = 0.079).
Conclusions
Our retrospective real-world study demonstrates that, compared to TKI monotherapy, the combination of ICI and TKI significantly improves progression-free survival (PFS), objective response rate (ORR), and overall survival (OS) in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC), with manageable safety. This study provides stronger evidence for the pharmacological treatment of metastatic non-clear cell renal cell carcinoma.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract